Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of metastatic uveal melanoma

Economic burden and healthcare resource utilization

4 evidence topics · 6 sources

Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims
Treatment group (Commercial and Medicare patients)Mean all-cause healthcare costs per patient per month (2025 US$)Mean adverse event-related costs per patient per month (2025 US$)Adverse event-related costs as a percentage of all-cause costs
All patients (n=423)“$28,859”“$2,607”“9.0%”
Chemotherapy (n=77)“$30,682”“$3,944”“12.9%”
Checkpoint inhibitors (n=145)“$36,056”“$4,158”“11.5%”
Tebentafusp (n=39)“$93,805”“$6,746”“7.2%”
Liver directed therapy (n=80)“$35,509”“$3,078”“8.7%”
Inpatient administration of tebentafusp during dose escalation in practice